What is Prodo Laboratories?
Founded in 2006, Prodo Laboratories operates as a specialized service provider dedicated to the procurement and processing of human and animal islets. The company serves as a vital link in the drug development pipeline, offering essential services such as islet isolations, specialized assays, and project-based consulting. Through its partnership with the Scharp-Lacy Research Institute, Prodo Laboratories provides high-quality biological materials that are indispensable for researchers investigating insulin-producing cells and novel diabetes therapies.
The company's market position is defined by its technical expertise in islet isolation efficiency, a critical bottleneck in metabolic disease research. By providing standardized, high-quality research materials, Prodo Laboratories enables pharmaceutical entities to accelerate their preclinical drug development cycles, thereby maintaining a competitive edge in the life sciences sector.
How much funding has Prodo Laboratories raised?
Prodo Laboratories has raised a total of $374K across 2 funding rounds:
Debt
$150K
Debt
$224K
Debt (2020): $150K with participation from PPP
Debt (2021): $224K led by PPP
Key Investors in Prodo Laboratories
PPP
Public-Private Partnership
What's next for Prodo Laboratories?
With the recent infusion of capital, Prodo Laboratories is well-positioned to deepen its integration into the pharmaceutical R&D ecosystem. The strategic focus will likely shift toward scaling production capabilities and broadening the scope of its consulting services to address emerging challenges in regenerative medicine and metabolic research. As the company matures, the emphasis will remain on maintaining the high-quality standards required for clinical-grade research while exploring new collaborative opportunities that leverage its unique expertise in islet biology. This late-stage financial stability provides the necessary runway to sustain long-term innovation in the fight against diabetes.
See full Prodo Laboratories company page
